Feb 17, 2023 / 09:00AM GMT
Operator
Good day and thank you for standing by, and welcome to Xbrane Biopharma presentation of year-end report 2022. (Operator Instructions)
I would now like to turn to the conference over to CEO Martin Ãmark. Please go ahead, sir.
Martin Ãmark - Xbrane Biopharma AB - CEO
Thank you very much and welcome all of you listening to our call where we're going to present Q4 report of 2022 for Xbrane. So first, I'm just going to provide a brief update on our recent biosimilar candidates in our portfolio, the progress we've made during 2022, and what's ahead of us during the course of 2023.
We start with our Lucentis biosimilar. I think we've made great progress during 2022. Of course, most importantly, we got an approval from EMA for the products that have -- so that it now can be launched by our partner STADA across Europe, which is going to take place this quarter. And I'm going come back to that in a later page.
And we worked a lot on the BLA for the regulatory submission to FDA for approval in the US. As all of you probably are aware, we had to
Q4 2022 Xbrane Biopharma AB Earnings Call Transcript
Feb 17, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers